This paper provides case studies of several food product improvement policies from across the WHO European Region. The aim is to share country experience, assess the various merits of the different approaches, discuss lessons learned, and provide guidance for best practice that may be more widely ap...plicable across the European Region.
more
A workshop of “first mover” countries to exchange experience and identify wider policy implications for the WHO European Region
The World Health Organization (WHO) European Region continues to be severely affected by diet-related noncommunicable diseases (NCDs), obesity and, in some countries, ...micronutrient deficiencies.
In order to drive further progress on improving dietary intake and food product improvement, the WHO Regional Office for Europe, Public Health England and the Royal Institute of International Affairs (Chatham House) co-convened a workshop of “first mover” countries in March 2019.
more
The WHO European Office for the Prevention and Control of Noncommunicable Diseases organized an expert meeting on monitoring of digital marketing of unhealthy products to children and adolescents in June 2018. Based on that meeting, this report aims to provide a tool to support Member States in moni...toring digital marketing of unhealthy products to children; the resulting tool – the so-called CLICK monitoring framework – is flexible and can be adapted to national context. The report also describes current digital marketing strategies, the challenges arising from current practices, and some policy options to tackle digital marketing to children and adolescents.
more
The purpose of this TPP is to communicate the minimum and ideal characteristics desired to meet the need for discriminating low levels of risk for transmission, i.e. targeted prevalence thresholds in the surveyed areas. An in vitro diagnostic test is needed for the detection of analyte(s) specific t...o Wuchereria bancrofti, Brugia malayi, and Brugia timori to aid in the surveillance of defined geographic areas as to whether infection and/or transmission potential has increased (recrudescence) or decreased (elimination of transmission).
more
Despite the development of point-of-care diagnostic tests for syphilis, chlamydia, gonorrhoea, and trichomoniasis, none comply with all WHO criteria. This analysis overviews landscape analyses of point-of-care diagnostic technologies for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vagi...nalis and syphilis, available and in the pipeline. The target audience for the target product profiles is broad and includes clinicians, researchers working on diagnostics, laboratory experts, including, microbiologists and virologists, public health experts, epidemiologists, developers, and representatives for manufactures, including biotech engineers, policy-and decision-makers as well as representatives from regulatory bodies and agencies, donor agencies and international organizations.
more
PQDx 0033-013-00 WHO
PQ Public Report
July/2016, version 5.0
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
PQDx 0053-006-00 WHO
PQ Public Report
June/2016, version 2.0
PQDx 0005-005-00
WHO PQDx PR
May/2016, version 3.0
PQDx 0159-055-00
WHO PQ Public Report
February/2017, version 5.0
Public Report
PQMC 0003-003-00 WHO PQMC PR June/2015, version 2.0
Rwanda Guidelines for variation to registered pharmaceutical products.
This guideline is intended to provide requirements to applicants wishing to submit
applications for registration of medicines in Botswana.
PQDx 0214-064-00
WHO PQDx PR
April/2016, version 3.0
PQDx 0198-071-00
WHO PQDx PR
April/2016, version 2.0
PQDx 0179-012-00 WHO
PQDx Public Report
June/2017, version 4.0
PQDx 0144-043-00 WHO
PQDx Public Report
November/2016, version 4.0
PQDx 0027-012-00 WHO
PQDx Public Report
May/2017, version 4.0